Tests mRNA-4106 and mRNA-4200 alone or with cancer drugs in advanced solid tumors
Tests safety of two mRNA treatments in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
Key facts
- Where
- Grand Rapids, Los Angeles, San Antonio, and West Valley City, United StatesSee the 4 sites
- Phase
- Phase 1
Where in United States
- START | MidwestGrand Rapids, United StatesTaking people
- START - Los AngelesLos Angeles, United StatesNot yet recruiting
- START | San AntonioSan Antonio, United StatesTaking people
- START Mountain RegionWest Valley City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ModernaTX, Inc.
- Trial code
- NCT06880549
- Record updated
- 13 October 2026
- Original description
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.Read full original descriptionShow less
A Phase 1, Open-label, Multicenter, Dose-escalation Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
Inclusion: Arm 1: Histologically confirmed advanced or metastatic cancer (cutaneous melanoma, non-small cell lung cancer [NSCLC], hepatocellular carcinoma [HCC], esophageal carcinoma, head and neck squamous cell carcinoma [HNSCC], colon/rectal adenocarcinomas, urothelial/bladder, gastric, ovarian, cervical, and endometrial carcinomas) with measurable disease as determined by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) and have completed or refused all standard therapies (no limit to prior lines of therapy). Participants must have a tumor lesion amenable to biopsy, or alternatively archival tumor tissue is acceptable as long as the collection date is within one year of the enrollment date; Arm 2: Histologically confirmed advanced or metastatic cancer (cutaneous melanoma, NSCLC, esophageal carcinoma, HNSCC, urothelial/bladder carcinoma, gastric, colon/rectal adenocarcinomas, ovarian, cervical, and endometrial carcinomas [Note: HCC not included]) with measurable disease as determined by RECIST v1.1 and have completed or refused all standard therapies (no more than 5 prior lines of therapy in the advanced/metastatic disease setting). Participants must have archival or fresh tumor tissue available for submission at Screening; Arm 2: Participant life expectancy of ≥90 days; Arm 1 and Arm 2: Participant has an Eastern Cooperative Oncology Group performance status of ≤1; Arm 1 and Arm 2: Participant has adequate hematological and biological function; Arm 1 and Arm 2: Participants who could become pregnant: negative highly sensitive pregnancy test within 24 hours before the first dose of study treatment.
Exclusion: Arm 1 and Arm 2: Participant has received treatment with prohibited medications/treatments (that is, concurrent anticancer therapy including other chemotherapy, hormonal anticancer therapy, biologic therapy, or immunotherapy) or investigational agents within 5 half-lives or 14 days prior to the first day of study treatment (Cycle 1 Day 1), whichever is shorter; Arm 1 and Arm 2: Participant has required the use of immunosuppressive doses of systemic steroids or absorbed topical steroids (doses >10 milligrams [mg] prednisone daily equivalent) within 2 weeks before study treatment administration or currently requiring maintenance doses of >10 mg prednisone or equivalent per day; Arm 1 and Arm 2: Participant has any plan to receive a live attenuated vaccine during study treatment or has received a live vaccine within 30 days before the first dose of study treatment; Arm 1 and Arm 2: Participant has any unstable or clinically significant concurrent medical/psychiatric illness or social situation that would limit compliance with study requirements or compromise the ability of the participant to provide written informed consent, per the discretion of the Investigator; Arm 1 and Arm 2: Participant has concurrent enrollment in another clinical study (unless it is an observational noninterventional clinical study); Note: Other inclusion and exclusion criteria may apply; Arm 1 and Arm 2: Participant has reversible toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline. Any unresolved toxicity National Cancer Institute Common Terminology Criteria for Adverse Events Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and prespecified laboratory values; Arm 1 and Arm 2: Participant has active central nervous system tumors or metastases.